Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/1997
03/27/1997WO1997011087A1 L-nucleoside dimer compounds and therapeutic uses
03/27/1997WO1997011079A1 Novel imidazole lipoxygenase inhibitors
03/27/1997WO1997011073A1 Novel substituted azacyclic or azabicyclic compounds
03/27/1997WO1997011072A1 Novel substituted azacyclic or azabicyclic compounds
03/27/1997WO1997011071A1 Novel heterocyclic compounds
03/27/1997WO1997011069A1 Heterocyclic compounds as bradykinin antagonists
03/27/1997WO1997011068A1 Novel pyridonecarboxylic acid derivatives or their salts and antibacterial agent comprising the same as the active ingredient
03/27/1997WO1997011061A1 Compounds potentiating retinoid
03/27/1997WO1997011056A1 Indole derivatives as melatoninergic analogues
03/27/1997WO1997011053A1 Calcitriol derivatives and their uses
03/27/1997WO1997010854A1 (radio) labelled biotin derivatives
03/27/1997WO1997010849A1 Copolymeric micelle drug composition and method for the preparation thereof
03/27/1997WO1997010847A1 Targeting of conjugates of poly(ethylene glycol) and antibodies against glutamic acid decarboxylase to islet cells
03/27/1997WO1997010844A1 Improved methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines
03/27/1997WO1997010840A1 Anti-inflammatory antisense drug
03/27/1997WO1997010837A1 Tumor rejection antigens presented by hla-b44 molecules, and uses thereof
03/27/1997WO1997010836A1 Peptides and peptidomimetics inhibiting the oncogenic action of p21 ras
03/27/1997WO1997010835A1 Anti-intoxication composition
03/27/1997WO1997010834A1 Bioactive factors of aloe vera plants
03/27/1997WO1997010830A1 REACTION PRODUCT OF ARGININE AND p-AMINOBENZOIC ACID
03/27/1997WO1997010829A1 Pharmaceutical compositions containing an oligonucleotide and an anionic polysaccharide
03/27/1997WO1997010828A1 Therapy for tissue membrane insufficiency
03/27/1997WO1997010827A1 Use of antimineralocorticoid compounds against drug withdrawal syndrome
03/27/1997WO1997010826A1 Pharmaceutical formulation
03/27/1997WO1997010825A1 SELECTIVE β3 ADRENERGIC AGONISTS
03/27/1997WO1997010824A1 Use of 5ht1b receptor antagonist for the treatment of vascular disease
03/27/1997WO1997010823A1 5-ht3 receptor antagonists for dyskinesia
03/27/1997WO1997010822A1 SELECTIVE β3 ADRENERGIC AGONISTS
03/27/1997WO1997010821A1 Enhancement of erectile function with renin-angiotensin system inhibitors
03/27/1997WO1997010820A1 Stable vitamin c preparation
03/27/1997WO1997010819A1 Treating niddm with rxr agonists
03/27/1997WO1997010818A1 Method and composition for treating mammalian diseases caused by inflammatory response
03/27/1997WO1997010817A1 Amino ceramide-like compounds and therapeutic methods of use
03/27/1997WO1997010816A1 METHODS OF TREATING β-AMYLOID-ASSOCIATED CONDITIONS
03/27/1997WO1997010815A1 The preparation of topical regional compositions for the relief of pain
03/27/1997WO1997010814A1 Propofol nanodispersions
03/27/1997WO1997010813A1 Ppar gamma antagonists for treating obesity
03/27/1997WO1997010811A1 Nanoparticles in photodynamic therapy
03/27/1997WO1997010810A2 Pharmaceutical granules
03/27/1997WO1997010809A1 Lyophilized thioxanthenone antimumor agents
03/27/1997WO1997010808A1 Lipoic acid in topical compositions
03/27/1997WO1997010806A1 Aerosol compositions
03/27/1997WO1997010805A1 Ophthalmic compositions containing cyclodextrins and quaternary ammonium compounds
03/27/1997WO1997010800A2 Antiplaque oral composition
03/27/1997WO1997010796A2 MANIPULATION AND DETECTION OF PROTEIN PHOSPHATASE 2C - PP2Cα - EXPRESSION IN TUMOR CELLS FOR CANCER THERAPY, PREVENTION AND DETECTION
03/27/1997WO1997010712A1 Inhibition of tumor necrosis factor alpha
03/27/1997WO1997010711A1 Methods and compositions for suppressing an immune response using major histocompatibility complex (mhc) class ii peptides
03/27/1997WO1997007795A3 1-[4-(4'-sulfanilyl)phenyl]urea and derivatives for the treatment of leishmaniasis
03/27/1997WO1997005875A3 A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
03/27/1997WO1997005873A3 Use of fluconazole for inhibiting the growth of cancers
03/27/1997WO1997005872A3 Use of 1h-1,2,4-triazole derivatives for inhibiting the growth of cancers
03/27/1997WO1997005859A3 Use of alicyclic diamines as immunomodulators
03/27/1997WO1997005253A3 Transketolase-related protein
03/27/1997WO1997004788A3 Use of calendula glycosides for the treatment of psoriasis
03/27/1997WO1997004780A3 Pain-alleviating drug composition and method for alleviating pain
03/27/1997WO1997004750A3 Process for preparing solid dosage forms of very low-dose drugs
03/27/1997WO1997002829A3 Use of indigestible oligosaccharides to prevent and treat diarrhea
03/27/1997WO1997001344A3 Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
03/27/1997WO1996040728A3 Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (nhe), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the nhe-inhibitory efficacy of compounds
03/27/1997WO1996040273A3 Conjugates of ferrites and oligonucleotides, which bond specifically to certain target structures
03/27/1997WO1996040043A3 Neuroactive steroids of the androstane and pregnane series
03/27/1997WO1996039156A3 Phosphate-binding polymers for oral administration
03/27/1997WO1996039153A3 Use of di-beta-d-glucopyranosylamine compounds for controlling inflammatory reactions, and method of synthesis
03/27/1997WO1996029974A3 Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
03/27/1997DE19537494A1 Kreatin zum Schutz von neuralem Gewebe Creatine to protect neural tissue
03/27/1997CA2658039A1 Human growth hormone variants
03/27/1997CA2233012A1 Compounds enhancing the activity of retinoids
03/27/1997CA2232838A1 Antiplaque oral composition
03/27/1997CA2232834A1 Targeting of conjugates of poly(ethylene glycol) and antibodies against glutamic acid decarboxylase to islet cells
03/27/1997CA2232750A1 Peptides and peptidomimetics inhibiting the oncogenic action of p21 ras
03/27/1997CA2232724A1 Modified protein kinase a-specific oligonucleotides and methods of their use
03/27/1997CA2232515A1 Parainfluenza virus glycoproteins and vaccines
03/27/1997CA2232444A1 Lyophilized thioxanthenone antitumor agents
03/27/1997CA2232434A1 Selective .beta.3 adrenergic agonists
03/27/1997CA2232411A1 (radio) labelled biotin derivatives
03/27/1997CA2232360A1 Enhancement of erectile function with renin-angiotensin system inhibitors
03/27/1997CA2232301A1 Pskh-1 ribozymes and uses in disease treatment
03/27/1997CA2232193A1 Dna encoding medicinal proteins
03/27/1997CA2232090A1 Selective .beta.3 adrenergic agonists
03/27/1997CA2231887A1 5-ht3 receptor antagonists for dyskinesia
03/27/1997CA2231835A1 Novel heterocyclic compounds
03/27/1997CA2231806A1 Dna construct comprising a muscle specific regulatory element for immunization or gene therapy
03/27/1997CA2231251A1 Histone deacetylase as target for antiprotozoal agents
03/27/1997CA2230119A1 Methods and compositions for suppressing an immune response using major histocompatibility complex (mhc) class ii peptides
03/27/1997CA2229796A1 Anti-intoxication composition
03/27/1997CA2229285A1 Nanoparticles in photodynamic therapy
03/27/1997CA2227306A1 Manipulation and detection of protein phosphatase 2c - pp2c.alpha. - expression in tumor cells for cancer therapy, prevention and detection
03/27/1997CA2206878A1 L-nucleoside dimer compounds and therapeutic uses
03/27/1997CA2183917A1 Preparation of optically active (s)-(-) and (r)-(+)- deoxyspergualin and novel intermediates thereof
03/26/1997EP0764722A2 DNA encoding primate leptins as medicinal proteins
03/26/1997EP0764659A1 Use of cyclodextrins and their derivatives for solubilising compounds of the Ginkgolide family
03/26/1997EP0764655A1 Cationic unsaturated saccharides, polymers produced from them and their use
03/26/1997EP0764647A1 Substituted xanthins
03/26/1997EP0764645A1 Novel 3,4-diaryl furans and analogs thereof having use as anti-inflammatory agents
03/26/1997EP0764644A1 Use of medicaments containing 3,4-diaryl furans and analogs thereof for treating a gastrointestinal condition
03/26/1997EP0764640A1 Selective beta3 adrenergic agonists
03/26/1997EP0764637A2 2-Cyano-3-mercaptocrotonamides
03/26/1997EP0764632A2 Selective beta3 adrenergic agonists
03/26/1997EP0764443A1 Ameliorant or remedy for paraneoplastic syndrome
03/26/1997EP0764442A1 Use of specific sulphur containing aminos acid derivatives against pathogenic viral or prion particles
1 ... 6812 6813 6814 6815 6816 6817 6818 6819 6820 6821 6822 6823 6824 6825 6826 6827 6828 6829 6830 6831 6832 ... 7860